profit from every $100 of sales.
$0$100
Arcutis Biotherapeutics
$26.20+2.54% today
+8.1% in 1 year
1-year low $19.501-year high $34.05
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Arcutis Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $3.69 million in 2022 to $376 million in 2025, with -$16.1 million of profit last year.
SalesProfit
Arcutis Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arcutis Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Arcutis Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | 60 | 197 | 376 | |
| 3 | 55 | 177 | 339 | |
| -302 | -241 | -128 | -12 | |
| -295 | -229 | -110 | 2 | |
| -311 | -262 | -140 | -16 | |
| -5.66 | -3.78 | -1.16 | -0.13 | |
| 79.5% | 91.6% | 90.3% | 90.2% | |
| -8,183.0% | -404.5% | -65.3% | -3.3% | |
| -8,449.8% | -439.8% | -71.3% | -4.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 449 | 341 | 349 | 433 |
| Cash | 54 | 88 | 71 | 43 |
| Total debt | 203 | 206 | 110 | 114 |
| Total liabilities | 240 | 253 | 191 | 243 |
| 210 | 89 | 158 | 189 | |
| 55 | 69 | 121 | 127 | |
| -56.7% | -61.5% | -33.2% | -0.8% | |
| -148.6% | -295.6% | -88.9% | -8.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -258 | -247 | -112 | -6 | |
| 23 | 0 | 5 | 11 | |
| -281 | -247 | -117 | -16 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 33 | 39 | 42 | 40 |
Valuation
- –
- 98.5×
- –
- 14.5×
- 8.8×
- –
- 1,901.4×
- -0.5%
- -0.5%
- 0.0%
Profitability
- 90.2%
- -3.3%
- -4.3%
- 3.1%
- 1.1%
- -56.0%
- -1.4%
- -0.5%
- 1.1%
- 21.7%
Growth
- +367.3%
- –
- +94.4%
- –
- +26.7%
Financial health
- 40.1×
- 0.07
- 2.9%
- 0.2×
- 2.68
- 2.46
- 0.90
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 39%of 948
Bottom 19%of 871
Bottom 37%of 985
What analysts expect
- Average price target
- $35.50
- Range
- $34.00 – $37.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.09 | -0.02 | −350.0% |
| Feb 25, 2026 | 0.13 | 0.03 | +333.3% |
| Oct 28, 2025 | 0.06 | -0.10 | +160.0% |
| Aug 6, 2025 | -0.13 | -0.18 | +27.8% |
| May 6, 2025 | -0.20 | -0.21 | +4.8% |
| Feb 25, 2025 | -0.09 | -0.28 | +67.9% |
| Nov 6, 2024 | -0.33 | -0.42 | +21.4% |
| Aug 14, 2024 | -0.42 | -0.48 | +12.5% |
News
Arcutis Biotherapeutics advances 11% to new 52-week highSeeking Alpha · Oct 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
39No pass
Philip Fisher
38No pass
Peter Lynch
52No pass
Joel Greenblatt
2No pass
Charlie Munger
25No pass
Terry Smith
20No pass
Questions about Arcutis Biotherapeutics
Is Arcutis Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arcutis Biotherapeutics AI analysis
What does Arcutis Biotherapeutics do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. It is in Biotechnology, based in Westlake Village, CA, United States, with 354 employees.
Does Arcutis Biotherapeutics pay a dividend?
No. Arcutis Biotherapeutics does not pay a dividend at the moment.
Is Arcutis Biotherapeutics stock halal?
Yes. Arcutis Biotherapeutics passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Arcutis Biotherapeutics stock done over the past year?
Up 8.1% over the past twelve months, to $26.20. It traded between $19.50 and $34.05 and is 23.1% below its high.
Who are Arcutis Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Arcutis Biotherapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.